{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:22:10Z","timestamp":1790558530794,"version":"4.1.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018987","name":"Romanian Government Ministry of Research Innovation and Digitization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018987","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ijbiomac.2024.139186","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T02:14:31Z","timestamp":1735179271000},"page":"139186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Antisense oligonucleotides-based approaches for the treatment of multiple myeloma"],"prefix":"10.1016","volume":"291","author":[{"given":"Madalina","family":"Oprea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Ionita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2024.139186_bb0005","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fphar.2019.00305","article-title":"Antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease","volume":"10","author":"Di Fusco","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nrc1631","article-title":"Antisense therapy for cancer","volume":"5","author":"Gleave","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0020","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1208\/aapsj070109","article-title":"DNA-based therapeutics and DNA delivery systems: a comprehensive review","volume":"7","author":"Patil","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.36253\/Substantia-964","article-title":"History of research on antisense oligonucleotide analogs","volume":"5","author":"Cohen","year":"2021","journal-title":"Substantia"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0030","doi-asserted-by":"crossref","unstructured":"V.V Oberemok, K.V. Laikova, A.I. Repetskaya, I.M. Kenyo, M.V. Gorlov, I.N. Kasich, et al.,A half-century history of applications of antisense oligonucleotides in medicine, agriculture and forestry: we should continue the journey, Molecules 23 (2018) 1302.","DOI":"10.3390\/molecules23061302"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0035","series-title":"Comprehensive Natural Products Chemistry","first-page":"285","article-title":"DNA with altered backbones in antisense applications","author":"Sanghvi","year":"1999"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0040","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0076-6879(04)87013-7","article-title":"Requirements for delivery of active antisense oligonucleotides into cells with lipid carriers","author":"J\u00e4\u00e4skel\u00e4inen","year":"2004"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0050","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1054-3589(08)60470-6","article-title":"Gene therapy and vascular disease","author":"Kibbe","year":"1999"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0055","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/asheducation-2003.1.248","article-title":"Advances in biology and therapy of multiple myeloma","volume":"2003","author":"Barill\u00e9-Nion","year":"2003","journal-title":"Hematology"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1042\/CS20050284","article-title":"Antisense therapy in malignant diseases: status quo and quo vadis?","volume":"110","author":"Tamm","year":"2006","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0065","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1038\/sj.onc.1206812","article-title":"The future of antisense therapy: combination with anticancer treatments","volume":"22","author":"Biroccio","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-5002(03)00147-8","article-title":"Antisense oligonucleotides for cancer therapy\u2014an overview","volume":"41","author":"Stahel","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0075","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.3390\/ijms22073295","article-title":"Recent advances in oligonucleotide therapeutics in oncology","volume":"22","author":"Xiong","year":"2021","journal-title":"Int. J. Molec. Sci."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0080","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hum.2015.070","article-title":"Oligonucleotide therapies: the past and the present","volume":"26","author":"Lundin","year":"2015","journal-title":"Hum. Gen. Ther."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0085","series-title":"Antisense RNA Design, Delivery, and Analysis","first-page":"3","article-title":"Introduction and history of the chemistry of nucleic acids therapeutics, inV","author":"Gait","year":"2022"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"27","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1006304","article-title":"A perspective on oligonucleotide therapy: approaches to patient customization","volume":"13","author":"Thakur","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2023.100166","article-title":"Antisense oligonucleotide based therapeutics and its applications against bacterial infections","volume":"20","author":"Angrish","year":"2023","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/aian.AIAN_298_17","article-title":"Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases","volume":"21","author":"Verma","year":"2018","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0115","article-title":"The powerful world of antisense oligonucleotides: from bench to bedside","volume":"Rev.RNA11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0120","first-page":"275","article-title":"Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics","volume":"2","author":"Mansoor","year":"2008","journal-title":"Gene. Reg. System. Biol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/17425255.2013.737320","article-title":"Clinical pharmacokinetics of second generation antisense oligonucleotides","volume":"9","author":"Yu","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0130","doi-asserted-by":"crossref","unstructured":"Y. Zhang, L. Lu, F. Song, X. Zou, Y. Liu, X. Zheng X, et al.,Research progress on non-protein-targeted drugs for cancer Therapy J. Exp. Clin. Cancer Res. 42(2023) 62.","DOI":"10.1186\/s13046-023-02635-y"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: a review","volume":"296","author":"Crooke","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0140","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0145","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1182\/blood-2019-124391","article-title":"Specific targeting of KRAS using a novel high-affinity KRAS antisense oligonucleotide in multiple myeloma","volume":"134","author":"Sacco","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s43088-022-00202-6","article-title":"Antisense oligonucleotides: recent progress in the treatment of various diseases","volume":"11","author":"Gopi","year":"2022","journal-title":"Beni-Suef Univ. J. Basic Appl. Sci."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0155","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40824-022-00292-4","article-title":"Nonviral delivery systems for antisense oligonucleotide therapeutics","volume":"26","author":"Huang","year":"2022","journal-title":"Biomater. Res."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0165","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jconrel.2022.10.050","article-title":"Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics","volume":"352","author":"Ramasamy","year":"2022","journal-title":"J. Controll. Rel."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0170","doi-asserted-by":"crossref","unstructured":"C.S.M. Fernandes, G.D.G Teixeira, O. Iranzo, A.C.A Roque, Engineered protein variants for bioconjugation, in B. Sarmento, J. das Neves(Eds.),Biomedical Applications of Functionalized Nanomaterials, Elsevier, 2018, pp. 105\u201338.","DOI":"10.1016\/B978-0-323-50878-0.00005-7"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.addr.2015.02.002","article-title":"Bioconjugates for targeted delivery of therapeutic oligonucleotides","volume":"87","author":"Ming","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0180","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/acs.bioconjchem.8b00761","article-title":"Bioconjugated oligonucleotides: recent developments and therapeutic applications","volume":"30","author":"Benizri","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0185","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.omtn.2019.02.024","article-title":"Delivery of GalNAc-conjugated splice-switching ASOs to non-hepatic cells through ectopic expression of asialoglycoprotein receptor","volume":"16","author":"Scharner","year":"2019","journal-title":"Molec. Ther. Nuc. Acid."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0190","doi-asserted-by":"crossref","unstructured":"P. Tran, T. Weldemichael, Z. Liu, H.Y Li,Delivery of oligonucleotides: Efficiency with lipid conjugation and clinical outcome, Pharmaceutics 14(2022) 342.","DOI":"10.3390\/pharmaceutics14020342"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0195","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.3390\/molecules26175420","article-title":"Chemistry of peptide-oligonucleotide conjugates: a review","volume":"26","author":"Klabenkova","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0200","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/jcm10040838","article-title":"Antibody-oligonucleotide conjugates: a twist to antibody-drug conjugates","volume":"10","author":"Dugal-Tessier","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0205","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.omtn.2020.11.016","article-title":"Base-modified aptamers obtained by cell-internalization SELEX facilitate cellular uptake of an antisense oligonucleotide","volume":"23","author":"Tanaka","year":"2021","journal-title":"Molec. Ther. Nuc. Acid."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0210","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.3390\/ijms21093252","article-title":"Aptamers and antisense oligonucleotides for diagnosis and treatment of hematological diseases","volume":"21","author":"Giudice","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0215","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1021\/acs.molpharmaceut.0c01238","article-title":"Advances in the design of (nano)formulations for delivery of antisense oligonucleotides and small interfering RNA: focus on the central nervous system","volume":"18","author":"Mendon\u00e7a","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0220","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticlesfrom liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0225","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2015.02.007","article-title":"Delivery of oligonucleotides with lipid nanoparticles","volume":"87","author":"Wang","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0230","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.omtn.2020.01.018","article-title":"Efficient delivery of antisense oligonucleotides using bioreducible lipid nanoparticles in vitro and in vivo","volume":"19","author":"Yang","year":"2020","journal-title":"Molec. Ther. Nucl. Acid."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0235","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/vaccines11030658","article-title":"Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines","volume":"11","author":"Swetha","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0240","first-page":"1435","volume":"15","author":"Gupta","year":"2023","journal-title":"Versatility of liposomes for antisense oligonucleotide delivery: A special focus on various therapeutic areas"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0245","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/biomedicines9040433","article-title":"The challenges and strategies of antisense oligonucleotide drug delivery","author":"Gagliardi","year":"2021","journal-title":"Biomedicines9"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0250","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1006\/bbrc.1996.0668","article-title":"Myotonic dystrophy: antisense oligonucleotide inhibition of DMPK gene expression in vitro","volume":"221","author":"Galderisi","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0255","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2006.11.006","article-title":"Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect","volume":"117","author":"Zhang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00063030-200620010-00001","article-title":"The future of antisense oligonucleotides in the treatment of respiratory diseases","volume":"20","author":"Ulanova","year":"2006","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0265","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1006\/bbrc.1996.5762","article-title":"In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method","volume":"231","author":"Aoki","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0270","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/108729002761381294","article-title":"Development and effects of immunoliposomes carrying an antisense oligonucleotide against DHFR RNA and directed toward human breast cancer cells overexpressing HER2","volume":"12","author":"Rodr\u00edguez","year":"2002","journal-title":"Antisense Nuc. Acid. Drug. Dev."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0275","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jconrel.2006.06.010","article-title":"In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug","volume":"114","author":"Pakunlu","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105218","article-title":"Exosome-mediated delivery of antisense oligonucleotides targeting \u03b1-synuclein ameliorates the pathology in a mouse model of Parkinson's disease","volume":"148","author":"Yang","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.130728","article-title":"Exosome-mediated delivery and regulation in neurological disease progression","volume":"264","author":"Singh","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0290","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.omtn.2021.12.029","article-title":"Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells","volume":"27","author":"Adamus","year":"2022","journal-title":"Molec. Ther. Nuc. Acids"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0295","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jiec.2019.02.017","article-title":"Exosome-based antisense locked nucleic acid delivery for inhibition of type II collagen degradation in chondrocyte","volume":"74","author":"Jeong","year":"2019","journal-title":"J. Ind.Eng. Chem."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0300","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1021\/acs.molpharmaceut.2c00026","article-title":"Activity and tissue distribution of antisense oligonucelotide CT102 encapsulated with cytidinil\/cationic lipid against hepatocellular carcinoma","volume":"19","author":"Guan","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0305","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.omtn.2023.04.028","article-title":"Modified ASO conjugates encapsulated with cytidinil\/cationic lipids exhibit more potent and longer lasting anti-HCC effects, Molec","volume":"32","author":"Pan","year":"2023","journal-title":"Ther. Nucleic Acids"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0310","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11051-018-4225-3","article-title":"DNA nanostructure-directed assembly of metal nanoparticle superlattices","volume":"20","author":"Julin","year":"2018","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0315","article-title":"DNA nanotechnology","volume":"3","author":"Seeman","year":"2017","journal-title":"Nature Rev. Mater."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0320","doi-asserted-by":"crossref","unstructured":"R. Rajagopalan, J.V. Yakhmi, Nanotechnological approaches toward cancer chemotherapy, inA. Ficai, A.M. Grumezescu(Eds.),Nanostructures for cancer therapy, Elsevier, 2017, pp. 211\u201340.","DOI":"10.1016\/B978-0-323-46144-3.00008-8"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0325","first-page":"66","article-title":"DNA nanostructures for stimuli-responsive drug delivery","volume":"3","author":"Wang","year":"2022","journal-title":"Smart Mater. Med."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0330","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fchem.2020.00751","article-title":"Rationally designed DNA nanostructures for drug delivery","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0335","doi-asserted-by":"crossref","first-page":"23693","DOI":"10.1021\/acsami.8b07889","article-title":"Self-assembled double-bundle DNA tetrahedron for efficient antisense delivery","volume":"10","author":"Yang","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0340","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/acsami.9b20707","article-title":"Aptamer-functionalized DNA origami for targeted codelivery of antisense oligonucleotides and doxorubicin to enhance therapy in drug-resistant cancer cells","volume":"12","author":"Pan","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0345","doi-asserted-by":"crossref","unstructured":"S.A.C Lima, S. Reis,Polymeric carriers for biomedical and nanomedicine application, Polymers 13(2021) 1261.","DOI":"10.3390\/polym13081261"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0350","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bioactmat.2021.05.038","article-title":"Delivery of therapeutic oligonucleotides in nanoscale","volume":"7","author":"Wu","year":"2022","journal-title":"Bioactive Mater."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0355","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/nar\/28.21.4225","article-title":"Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers","volume":"28","author":"Yoo","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0360","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/710502","article-title":"A polyethylenimine-linoleic acid conjugate for antisense oligonucleotide delivery","volume":"2013","author":"Xie","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0365","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1287128","article-title":"A polyethylenimine-containing and transferrin-conjugated lipid nanoparticle system for antisense oligonucleotide delivery to AML","volume":"2016","author":"Yuan","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0370","doi-asserted-by":"crossref","unstructured":"H.S. Min, H.J. Kim, M. Naito, S. Ogura, K. Toh, Hayashi K, et al., Systemic brain delivery of antisense oligonucleotides across the blood-brain barrier with a glucose-coated polymeric nanocarrier, Angew. Chem. 59(2020) 8173\u201380.","DOI":"10.1002\/anie.201914751"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0375","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.progpolymsci.2010.04.007","article-title":"Hydrophobic modifications of cationic polymers for gene delivery","volume":"35","author":"Liu","year":"2010","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0380","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1166\/jnn.2008.1219","article-title":"Preparation and biophysical characterization of Pluronic F127-dendrimer conjugate as a delivery agent of antisense oligonucleotides","volume":"8","author":"Tran","year":"2008","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0385","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.009","article-title":"Poly(lactic acid) for delivery of bioactive macromolecules","volume":"107","author":"James","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0390","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jconrel.2006.12.021","article-title":"Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy","volume":"119","author":"Zhao","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0395","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/pharmaceutics15020520","article-title":"Cyclodextrin-based nanoparticles for delivery of antisense oligonucleotides targeting Huntington","volume":"15","author":"Mendon\u00e7a","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0400","first-page":"232","article-title":"Local delivery of c-myc antisense oligonucleotides during balloon angioplasty","volume":"41","author":"Azrin","year":"1997","journal-title":"Catheter Cardiovasc. Diagnosis"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0405","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0142-9612(01)00125-9","article-title":"The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides","volume":"23","author":"Chirila","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0410","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12951-022-01650-z","article-title":"Recent advances of metal-based nanoparticles in nucleic acid delivery for therapeutic applications","volume":"20","author":"Sharma","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112167","article-title":"Delivery of antisense oligonucleotides using multi-layer coated gold nanoparticles to methicillin-resistant S. Aureus for combinatorial treatment","volume":"126","author":"Beha","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0420","doi-asserted-by":"crossref","unstructured":"G.A. Kanu, J.B.M. Parambath, R.O. Abu Odeh, A.A. Mohamed,Gold nanoparticle-mediated gene therapy, Cancers14 (2022) 5366.","DOI":"10.3390\/cancers14215366"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0425","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/nat.2013.0450","article-title":"Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy","volume":"24","author":"Falzarano","year":"2014","journal-title":"Nucl. Acid. Ther."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2019.102127","article-title":"MXD3 antisense oligonucleotide with superparamagnetic iron oxide nanoparticles: a new targeted approach for neuroblastoma","volume":"24","author":"Yoshida","year":"2020","journal-title":"Nanomed.: Nanotechnol., Biol. Med."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0435","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/pharmaceutics12030233","article-title":"Gene therapy in cancer treatment: why go nano?","volume":"12","author":"Rodrigues","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0440","volume":"7","author":"Mostafavi","year":"2022","journal-title":"Carbon-based nanomaterials in gene therapy. OpenNano"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.flatc.2022.100417","article-title":"Graphene toxicity and future perspectives in healthcare and biomedicine","volume":"35","author":"Chiticaru","year":"2022","journal-title":"FlatChem"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0450","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1021\/nl071114c","article-title":"Intracellular delivery of quantum dots taggedantisenseoligodeoxynucleotides by functionalized multiwalled carbon nanotubes","volume":"7","author":"Jia","year":"2007","journal-title":"Nano Lett."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0455","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/bc800540j","article-title":"Conjugation of antisense oligonucleotides to PEGylated carbon nanotubes enables efficient knockdown of PTPN22 in T lymphocytes","volume":"20","author":"Delogu","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0460","article-title":"Reduced polydopamine coated graphene for delivery of Hset1 antisense as a photothermal and gene therapy of breast cancer","volume":"73","author":"Babavalian","year":"2022","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0465","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/biom14030366","article-title":"Solid phase oligo-DNA extraction from complex medium using an aminated graphene\/nitrocellulose membrane hybrid","volume":"14","author":"Toader","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0470","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/coatings10040420","article-title":"Oligonucleotide detection and optical measurement with graphene oxide in the presence of bovine serum albumin enabled by use of surfactants and salts","volume":"10","author":"Nitu","year":"2020","journal-title":"Coatings"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0475","doi-asserted-by":"crossref","unstructured":"F.R Nitu, L. Savu, S. Muraru, I. Stoian, M. Ionit\u0103,Label-free homogeneous microRNA detection in cell culture medium based on graphene oxide and specific fluorescence quenching, Nanomaterials 11(2021) 368.","DOI":"10.3390\/nano11020368"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0480","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcdb.2020.10.006","article-title":"Multiple myeloma - a painful disease of the bone marrow","volume":"112","author":"Diaz-delCastillo","year":"2021","journal-title":"Semin. Cell. Develop. Biol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0485","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154129","article-title":"Circular RNA in multiple myeloma: a new target for therapeutic intervention","volume":"238","author":"Ren","year":"2022","journal-title":"Pathol. Res. Practice"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100999","article-title":"The use of bone-modifying agents in multiple myeloma","volume":"57","author":"Hussain","year":"2023","journal-title":"Blood Rev."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0500","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.3390\/molecules25235776","article-title":"Antitumor drugs and their targets","volume":"25","author":"Dembic","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0505","series-title":"Role of Nutraceuticals in cancer Chemosensitization","first-page":"1","article-title":"Pathways linked to cancer chemoresistance and their targeting by nutraceuticals","author":"Bharti","year":"2018"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1061417","article-title":"Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews","volume":"12","author":"McKenzie","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0515","series-title":"Cancer Immunotherapy","first-page":"101","article-title":"Cytotoxic chemotherapy in clinical treatment of cancer","author":"Thirumaran","year":"2007"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0520","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0525","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12185-016-2008-0","article-title":"Histone deacetylase inhibitors in multiple myeloma: from bench to bedside","volume":"104","author":"Harada","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0530","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11523-020-00758-2","article-title":"Targeting nuclear export proteins in multiple myeloma therapy","volume":"15","author":"Theodoropoulos","year":"2020","journal-title":"Target. Oncol"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101143","article-title":"Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action","volume":"33","author":"Wudhikarn","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0540","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0545","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.3390\/molecules24132500","article-title":"Anti-multiple myeloma potential of secondary metabolites from Hibiscus sabdariffa","volume":"24","author":"Malacrida","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0550","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jcp.24791","article-title":"Gene therapies for cancer: strategies, challenges and successes","volume":"230","author":"Das","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0555","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s10439-012-0678-1","article-title":"Physical non-viral gene delivery methods for tissue engineering","volume":"41","author":"Mellott","year":"2013","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0560","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.carbon.2018.09.019","article-title":"Graphene-based nano-carrier modifications for gene delivery applications","volume":"140","author":"Imani","year":"2018","journal-title":"Carbon"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0565","article-title":"Disruption of immunoglobulin heavy and light chain assembly by antisense oligonucleotides impairs protein homeostasis and myeloma cell survival","author":"Horiot","year":"2023","journal-title":"BioRxiv"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0570","series-title":"Selective Killing of Plasma Cell Clones Using Splice-Switching Oligonucleotides Targeting Immunoglobulin Variable Exons, bioRxiv","author":"Lambert","year":"2024"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0575","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/sj.leu.2403363","article-title":"G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in vad refractory myeloma","volume":"18","author":"van de Donk","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0580","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/blood.V104.11.2400.2400","article-title":"Phase II trial of Oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in relapsed multiple myeloma patients","volume":"104","author":"Badros","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0585","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.leu.2402768","article-title":"Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein","volume":"17","author":"van de Donk","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0590","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xl is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0595","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/0008-5472.CAN-18-2799","article-title":"An HK2 antisense oligonucleotide induces synthetic lethality in HK1\u2212HK2+ multiple myeloma","volume":"79","author":"Xu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0600","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.stem.2020.12.017","article-title":"Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption","volume":"28","author":"Mondala","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0605","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2018-03-836601","article-title":"Therapeutic vulnerability of multiple myeloma to mir17PTi, a first-in-class inhibitor of pri-mir-17-92","volume":"132","author":"Morelli","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0610","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1172\/JCI115355","article-title":"Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines","volume":"88","author":"Levy","year":"1991","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0615","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood-2019-129286","article-title":"ILF2 antisense oligonucleotide therapy and a CRISPR\/Cas9-based screening for DNA repair effectors identify synthetic lethal approaches enhancing myeloma cells sensitivity to DNA damage","volume":"134","author":"Thongon","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0620","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/s41375-018-0067-3","article-title":"Drugging the lncRNA MALAT1 via LNA gapmer ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity","volume":"32","author":"Amodio","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0625","first-page":"58598","article-title":"Repression of multiple myeloma cell growth in vivo by single-wall carbon nanotube (SWCNT)-delivered MALAT1 antisense oligos","volume":"13","author":"Lin","year":"2018","journal-title":"J. Visual Exp."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0630","series-title":"The Molecular Basis of cancer","first-page":"19","article-title":"Oncogenes and signal transduction","author":"Grumolato","year":"2015"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0635","doi-asserted-by":"crossref","unstructured":"Z.H. Siddik, Apoptosis in cancer: Mechanisms, deregulation, and therapeutic targeting, inS. Neidle (Ed.), Cancer Drug Design and Discovery (Second Edition), San Diego, Academic Press, 2014, pp. 357\u201390.","DOI":"10.1016\/B978-0-12-396521-9.00012-7"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0640","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/cdd.2008.37","article-title":"Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?","volume":"15","author":"Labi","year":"2008","journal-title":"Cell. Death Diff."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0645","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biomaterials.2018.12.033","article-title":"Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo","volume":"197","author":"Ma","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2023.100077","article-title":"Hexokinases in cancer and other pathologies","volume":"2","author":"Guo","year":"2023","journal-title":"Cell. Insight"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.581208","article-title":"Hexokinase 2 promotes cell growth and tumor formation through the Raf\/MEK\/ERK signaling pathway in cervical cancer","volume":"10","author":"Cui","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0660","article-title":"A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors","volume":"12","author":"Li","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0665","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41389-020-00253-3","article-title":"Cyclin D1 targets hexokinase 2 to control aerobic glycolysis in myeloma cells","volume":"9","author":"Caillot","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0670","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers11050731","article-title":"STAT3: a promising therapeutic target in multiple myeloma","volume":"11","author":"Chong","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0675","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3390\/cells11060941","article-title":"Biological hallmarks and emerging strategies to target STAT3 signaling in multiple myeloma","volume":"11","author":"Zhou","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0680","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5045\/br.2017.52.4.293","article-title":"STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma","volume":"52","author":"Jung","year":"2017","journal-title":"Blood Res."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0685","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","author":"Crooke","year":"2007"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0690","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Trans. Med."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0695","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Molec. Cancer"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0700","first-page":"5647","article-title":"Oligonucleotide-based therapeutics for STAT3 targeting in cancer","volume":"15","author":"Molenda","year":"2023","journal-title":"Drug Carrier Matter. Cancer"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0705","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2018.07.025","article-title":"IRF4 in multiple myeloma\u2014biology, disease and therapeutic target","volume":"72","author":"Agnarelli","year":"2018","journal-title":"Leukemia Res."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0710","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-142518","article-title":"Mechanisms regulating myeloma cell responsiveness to antisense oligonucleotides targeting IRF4","volume":"136","author":"Shirasaki","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0715","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene \u2014 the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0720","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-20-2283","article-title":"Implications of MYC rearrangements in newly diagnosed multiple myeloma","volume":"26","author":"Abdallah","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0725","first-page":"842","article-title":"MYC inhibitors in multiple myeloma","volume":"4","author":"Mart\u00ednez-Mart\u00edn","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0730","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/cdd.2013.125","article-title":"The miR-17\/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease","volume":"20","author":"Mogilyansky","year":"2013","journal-title":"Cell. Death Different."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0735","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/cbir.2000.0497","article-title":"Role of interleukin-6 in the pathogenesis of multiple myeloma","volume":"24","author":"Gad\u00f3","year":"2000","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0740","series-title":"Systemic Lupus Erythematosus","first-page":"516","article-title":"New treatments in systemic lupus erythematosus","author":"Kyttaris","year":"2007"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0745","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0750","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.V97.2.483","article-title":"Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis","volume":"97","author":"Frassanito","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.006","article-title":"Revisiting IL-6 antagonism in multiple myeloma","volume":"105","author":"Matthes","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0760","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.608","article-title":"Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0765","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/cells10061360","article-title":"Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets","volume":"10","author":"Burroughs Garc\u00eca","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0770","first-page":"98","article-title":"Oncogene or tumor suppressor? Long noncoding RNAs role in patient\u2019s prognosis varies depending on disease type, Transl. Res","volume":"230","author":"Huang","year":"2021","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0775","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3892\/ijo.2023.5517","article-title":"Long non-coding RNAs in multiple myeloma","volume":"62","author":"Yang","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0780","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1038\/s41375-018-0104-2","article-title":"Targeting the MALAT1\/PARP1\/LIG3 complex induces DNA damage and apoptosis in multiple myeloma","volume":"32","author":"Hu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0785","series-title":"LINC01432 Binds to CELF2 in Newly Diagnosed Multiple Myeloma Promoting Short Progression-Free Survival to Standard Therapy, bioRxiv","author":"Mishra","year":"2024"},{"issue":"16","key":"10.1016\/j.ijbiomac.2024.139186_bb0790","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood.2023021991","article-title":"An unbiased lncRNAs dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma","volume":"144","author":"Grillone","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2022.0061","article-title":"Considerations in the preclinical assessment of the safety of antisense oligonucleotides","volume":"33","author":"Goyenvalle","year":"2023","journal-title":"Nuc. Acid. Ther."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0800","unstructured":"Clinical pharmacology considerations in the development of oligonucleotide therapeutics. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-considerations-development-oligonucleotide-therapeutics, 2024 (accesed 2 October 2024)."},{"key":"10.1016\/j.ijbiomac.2024.139186_bb0805","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.xphs.2024.04.021","article-title":"Areview on commercial oligonucleotide drug products","volume":"113","author":"Vinjamuri","year":"2024","journal-title":"J. Pharma. Sci."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024099975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024099975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:29:34Z","timestamp":1782926974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024099975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":161,"alternative-id":["S0141813024099975"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.139186","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense oligonucleotides-based approaches for the treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.139186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"139186"}}